CN116983466A - Medical gel dressing and preparation method and application thereof - Google Patents
Medical gel dressing and preparation method and application thereof Download PDFInfo
- Publication number
- CN116983466A CN116983466A CN202311040584.0A CN202311040584A CN116983466A CN 116983466 A CN116983466 A CN 116983466A CN 202311040584 A CN202311040584 A CN 202311040584A CN 116983466 A CN116983466 A CN 116983466A
- Authority
- CN
- China
- Prior art keywords
- dressing
- gel dressing
- polyethylene glycol
- medical gel
- medical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 145
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 144
- 108010039918 Polylysine Proteins 0.000 claims abstract description 74
- 208000027418 Wounds and injury Diseases 0.000 claims abstract description 42
- 206010052428 Wound Diseases 0.000 claims abstract description 41
- 229920000656 polylysine Polymers 0.000 claims abstract description 29
- 239000003814 drug Substances 0.000 claims abstract description 22
- 229940079593 drug Drugs 0.000 claims abstract description 20
- 239000000463 material Substances 0.000 claims abstract description 20
- 150000002334 glycols Chemical class 0.000 claims abstract description 16
- 230000001684 chronic effect Effects 0.000 claims abstract description 11
- 239000000853 adhesive Substances 0.000 claims abstract description 9
- 230000001070 adhesive effect Effects 0.000 claims abstract description 9
- 208000031737 Tissue Adhesions Diseases 0.000 claims abstract description 8
- 230000017423 tissue regeneration Effects 0.000 claims abstract description 7
- 229940030225 antihemorrhagics Drugs 0.000 claims abstract description 6
- 239000002874 hemostatic agent Substances 0.000 claims abstract description 6
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 26
- -1 succinimide ester Chemical class 0.000 claims description 21
- KZNICNPSHKQLFF-UHFFFAOYSA-N dihydromaleimide Natural products O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 15
- 230000000975 bioactive effect Effects 0.000 claims description 14
- 229960002317 succinimide Drugs 0.000 claims description 14
- 210000001519 tissue Anatomy 0.000 claims description 14
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims description 8
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 claims description 7
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 claims description 7
- 239000003102 growth factor Substances 0.000 claims description 6
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 5
- 102000013275 Somatomedins Human genes 0.000 claims description 5
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims description 4
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims description 4
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims description 4
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 claims description 4
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 claims description 4
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 4
- 235000013824 polyphenols Nutrition 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 235000005875 quercetin Nutrition 0.000 claims description 4
- 229960001285 quercetin Drugs 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 claims description 4
- 239000002262 Schiff base Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 230000004048 modification Effects 0.000 claims description 3
- 238000012986 modification Methods 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 claims description 2
- NMWKYTGJWUAZPZ-WWHBDHEGSA-N (4S)-4-[[(4R,7S,10S,16S,19S,25S,28S,31R)-31-[[(2S)-2-[[(1R,6R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,53S,56S,59S,62S,65S,68S,71S,76S,79S,85S)-47-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-18-(4-aminobutyl)-27,68-bis(3-amino-3-oxopropyl)-36,71,76-tribenzyl-39-(3-carbamimidamidopropyl)-24-(2-carboxyethyl)-21,56-bis(carboxymethyl)-65,85-bis[(1R)-1-hydroxyethyl]-59-(hydroxymethyl)-62,79-bis(1H-imidazol-4-ylmethyl)-9-methyl-33-(2-methylpropyl)-8,11,17,20,23,26,29,32,35,38,41,48,54,57,60,63,66,69,72,74,77,80,83,86-tetracosaoxo-30-propan-2-yl-3,4,44,45-tetrathia-7,10,16,19,22,25,28,31,34,37,40,49,55,58,61,64,67,70,73,75,78,81,84,87-tetracosazatetracyclo[40.31.14.012,16.049,53]heptaoctacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-7-(3-carbamimidamidopropyl)-25-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-28-(1H-imidazol-4-ylmethyl)-10-methyl-6,9,12,15,18,21,24,27,30-nonaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](Cc4ccccc4)NC3=O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(=O)N[C@@H](C)C(O)=O NMWKYTGJWUAZPZ-WWHBDHEGSA-N 0.000 claims description 2
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 claims description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 2
- 102000007644 Colony-Stimulating Factors Human genes 0.000 claims description 2
- 108010071942 Colony-Stimulating Factors Proteins 0.000 claims description 2
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 claims description 2
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 claims description 2
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 claims description 2
- 229920002079 Ellagic acid Polymers 0.000 claims description 2
- 108090000394 Erythropoietin Proteins 0.000 claims description 2
- 102000003951 Erythropoietin Human genes 0.000 claims description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims description 2
- IKMDFBPHZNJCSN-UHFFFAOYSA-N Myricetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC(O)=C(O)C(O)=C1 IKMDFBPHZNJCSN-UHFFFAOYSA-N 0.000 claims description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 claims description 2
- 102000006747 Transforming Growth Factor alpha Human genes 0.000 claims description 2
- 101800004564 Transforming growth factor alpha Proteins 0.000 claims description 2
- 229960000271 arbutin Drugs 0.000 claims description 2
- 210000000988 bone and bone Anatomy 0.000 claims description 2
- 229940074360 caffeic acid Drugs 0.000 claims description 2
- 235000004883 caffeic acid Nutrition 0.000 claims description 2
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 claims description 2
- 235000005487 catechin Nutrition 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 229950001002 cianidanol Drugs 0.000 claims description 2
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 claims description 2
- 235000012754 curcumin Nutrition 0.000 claims description 2
- 229940109262 curcumin Drugs 0.000 claims description 2
- 239000004148 curcumin Substances 0.000 claims description 2
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims description 2
- 229960002852 ellagic acid Drugs 0.000 claims description 2
- 235000004132 ellagic acid Nutrition 0.000 claims description 2
- 229940105423 erythropoietin Drugs 0.000 claims description 2
- 210000001808 exosome Anatomy 0.000 claims description 2
- 235000004515 gallic acid Nutrition 0.000 claims description 2
- 229940074391 gallic acid Drugs 0.000 claims description 2
- 150000004676 glycans Chemical class 0.000 claims description 2
- 235000008777 kaempferol Nutrition 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 claims description 2
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 claims description 2
- 230000000921 morphogenic effect Effects 0.000 claims description 2
- PCOBUQBNVYZTBU-UHFFFAOYSA-N myricetin Natural products OC1=C(O)C(O)=CC(C=2OC3=CC(O)=C(O)C(O)=C3C(=O)C=2)=C1 PCOBUQBNVYZTBU-UHFFFAOYSA-N 0.000 claims description 2
- 235000007743 myricetin Nutrition 0.000 claims description 2
- 229940116852 myricetin Drugs 0.000 claims description 2
- 239000002105 nanoparticle Substances 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 150000007523 nucleic acids Chemical class 0.000 claims description 2
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 claims description 2
- 229920001282 polysaccharide Polymers 0.000 claims description 2
- 239000005017 polysaccharide Substances 0.000 claims description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 2
- 239000006041 probiotic Substances 0.000 claims description 2
- 235000018291 probiotics Nutrition 0.000 claims description 2
- 230000035755 proliferation Effects 0.000 claims description 2
- 230000008439 repair process Effects 0.000 claims description 2
- 229940126586 small molecule drug Drugs 0.000 claims description 2
- 210000000130 stem cell Anatomy 0.000 claims description 2
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims 1
- 101800003838 Epidermal growth factor Proteins 0.000 claims 1
- 101000632994 Homo sapiens Somatostatin Proteins 0.000 claims 1
- 102000015336 Nerve Growth Factor Human genes 0.000 claims 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 claims 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 claims 1
- 102100029563 Somatostatin Human genes 0.000 claims 1
- 229940116977 epidermal growth factor Drugs 0.000 claims 1
- 229940126864 fibroblast growth factor Drugs 0.000 claims 1
- 229940053128 nerve growth factor Drugs 0.000 claims 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims 1
- 229960000553 somatostatin Drugs 0.000 claims 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims 1
- 239000002994 raw material Substances 0.000 abstract description 5
- 206010051373 Wound haemorrhage Diseases 0.000 abstract description 3
- 239000000499 gel Substances 0.000 description 111
- 239000000243 solution Substances 0.000 description 55
- 239000000017 hydrogel Substances 0.000 description 53
- 230000000844 anti-bacterial effect Effects 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 230000000694 effects Effects 0.000 description 12
- 230000002439 hemostatic effect Effects 0.000 description 12
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 12
- 230000029663 wound healing Effects 0.000 description 12
- 239000007788 liquid Substances 0.000 description 11
- 108010080379 Fibrin Tissue Adhesive Proteins 0.000 description 9
- 150000001299 aldehydes Chemical group 0.000 description 7
- 230000006835 compression Effects 0.000 description 6
- 238000007906 compression Methods 0.000 description 6
- 230000035876 healing Effects 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 6
- 230000008961 swelling Effects 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 5
- 208000032843 Hemorrhage Diseases 0.000 description 5
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 241000191967 Staphylococcus aureus Species 0.000 description 5
- 230000023597 hemostasis Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 230000000740 bleeding effect Effects 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000013065 commercial product Substances 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010056340 Diabetic ulcer Diseases 0.000 description 2
- 208000004210 Pressure Ulcer Diseases 0.000 description 2
- 108010087230 Sincalide Proteins 0.000 description 2
- 206010053615 Thermal burn Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 238000010609 cell counting kit-8 assay Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 238000001493 electron microscopy Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 238000002386 leaching Methods 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 230000037314 wound repair Effects 0.000 description 2
- 241000607534 Aeromonas Species 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 206010011985 Decubitus ulcer Diseases 0.000 description 1
- 208000008960 Diabetic foot Diseases 0.000 description 1
- 102000018386 EGF Family of Proteins Human genes 0.000 description 1
- 108010066486 EGF Family of Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 208000003790 Foot Ulcer Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- CWEZAWNPTYBADX-UHFFFAOYSA-N Procyanidin Natural products OC1C(OC2C(O)C(Oc3c2c(O)cc(O)c3C4C(O)C(Oc5cc(O)cc(O)c45)c6ccc(O)c(O)c6)c7ccc(O)c(O)c7)c8c(O)cc(O)cc8OC1c9ccc(O)c(O)c9 CWEZAWNPTYBADX-UHFFFAOYSA-N 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000007718 adhesive strength test Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000001804 debridement Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 238000013168 hemostasis test Methods 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 229920002414 procyanidin Polymers 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 239000003566 sealing material Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000002352 surface water Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0019—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/26—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0015—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0031—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/046—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/008—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/06—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/145—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/04—Materials for stopping bleeding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/06—Flowable or injectable implant compositions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Materials For Medical Uses (AREA)
Abstract
The application discloses a medical gel dressing, and a preparation method and application thereof. The medical gel dressing is mainly formed by solidifying polyethylene glycol derivatives and polylysine. The medical gel dressing has the advantages of high gel forming speed, excellent mechanical property, strong tissue adhesiveness, good biocompatibility, biodegradability and the like, and can be effectively used for plugging wound bleeding. The medical gel dressing can be used as a tissue wound plugging and repairing material, a hemostatic agent, a medical adhesive, a tissue adhesion preventing material, a drug slow-release material, a tissue regeneration bracket or a chronic wound dressing, and has good clinical application value. In addition, the medical gel dressing has rich sources of raw materials and low cost.
Description
Technical Field
The application relates to the technical field of medical gel, in particular to a medical gel dressing and a preparation method and application thereof.
Background
Various hemostatic sealing materials have been developed, including hemostatic bandages, hemostatic powders, hemostatic gels, and the like. Hemostatic bandages are difficult to apply to irregularly shaped wounds and cannot seal deep wounds; the adhesion and mechanical strength of the hemostatic powder are weak, and the hemostatic powder is easy to be washed away and lost by blood flow. The commercial fibrin glue has good biocompatibility and biodegradability, but has insufficient tissue adhesion and mechanical strength, poor hemostatic effect on massive hemorrhage, inconvenient storage, potential immunogenicity and allergic reaction and other problems.
The hydrogel is a soft material which is obtained by crosslinking a hydrophilic polymer and contains a large amount of water, and has good biocompatibility, high elasticity, softness, soft tissue water content-like property, three-dimensional porous network structure similar to a natural extracellular matrix and cell behavior regulation effect. In addition, the injectable gel can be applied to irregular wounds, effectively maintains the required moist environment of the wounds, promotes gas exchange, simultaneously isolates external infection, and has advantages in wound hemostasis and subsequent tissue healing modification.
Wound healing is particularly important after hemostasis is complete. Although human skin has the ability to regenerate itself after loss, this ability can be compromised under specific conditions such as extensive skin loss, deep burns, scalds, chronic wounds, pressure sores, arterial ulcers and injuries in diabetics. With the aging of the world population, there is an increasing demand for the treatment of chronic wounds such as decubitus ulcers and ulcers that are closely related thereto. The traditional gauze is used for treating wounds, so that patients need to change dressings frequently, the hospitalization time is long, the medical cost is high, and the compliance of the patients is poor. An ideal medical dressing should have the following conditions: (1) excellent tissue compatibility and non-toxicity; (2) suitable biodegradability; (3) good antibacterial activity; (4) good moisturizing ability to promote cell and tissue regeneration; (5) sufficient mechanical strength. The proper medical dressing is selected according to the type of the wound, so that the functions of stopping bleeding, preventing bacterial infection, debridement and the like can be realized in time, and the wound is promoted to be repaired as soon as possible according to the ordered wound healing process. However, the existing wound dressing has the disadvantages of higher cost, single function, insufficient antibacterial and anti-infection capabilities, and unsatisfactory effect when treating chronic wound surfaces which are difficult to heal.
Although, studies have shown that functional gel dressings can be prepared by loading bioactive components into the gel dressing or delivering functional drugs, which can accelerate healing of chronic wounds; however, how to prepare the multifunctional medical gel dressing with low cost, fast gelling speed, excellent mechanical property, strong tissue adhesiveness, good biocompatibility and biodegradability is still the research focus and difficulty in the field.
Disclosure of Invention
The application aims to provide a novel multifunctional medical gel dressing, and a preparation method and application thereof.
In order to achieve the above purpose, the present application adopts the following technical scheme:
one aspect of the application discloses a medical gel dressing which is mainly formed by solidifying polyethylene glycol derivatives and polylysine.
The medical gel dressing has the advantages of high gelling speed, excellent mechanical property, strong tissue adhesiveness, good biocompatibility, biodegradability and the like, and can be effectively used for plugging wound bleeding. In one implementation mode of the application, the medical gel dressing can load bioactive components and/or medicines, and has excellent functions of resisting bacteria and inflammation, promoting wound healing and repairing and the like. The medical gel dressing can be used as a tissue wound plugging and repairing material, a hemostatic agent, a medical adhesive, a tissue adhesion preventing material, a drug slow-release material, a tissue regeneration bracket, a chronic wound dressing and the like, and has good clinical application value. In addition, the medical gel dressing has the advantages of abundant raw material sources and low cost, and is suitable for large-scale industrialized mass production.
In one implementation of the application, the chemical bond formed by the chemical reaction in the curing process is a beta-carbonyl amide bond or a Schiff base bond.
In one implementation of the application, the medical gel dressing has a three-dimensional gel skeleton structure.
In one implementation mode of the application, the structural formula of the polylysine is at least one of the formula I, the formula II, the formula III and the formula IV;
wherein, m is an integer between 2 and 10000.
Preferably, the molecular weight of the polylysine is 292-300000, preferably 3500-10000.
In the application, polylysine with a structural formula I is epsilon-polylysine (EPL), polylysine with a structural formula II is poly-L-lysine (PLL), polylysine with a structural formula III is Hyperbranched Polylysine (HPL), and polylysine with a structural formula IV is Dendritic Polylysine (DPL).
In one implementation of the application, the polyethylene glycol derivative is a succinimide ester functionalized polyethylene glycol.
In one implementation of the application, the structural formula of the succinimide ester functionalized polyethylene glycol is at least one of formula V, formula VI, formula VII and formula VIII;
wherein n is an integer between 2 and 10000.
Preferably, the molecular weight of the succinimide ester-functionalized polyethylene glycol is 2000-20000, preferably 2000-10000.
In the application, the succinimide ester functionalized polyethylene glycol with the structural formula V is double-arm polyethylene glycol succinimide ester (PEG) 2 -NHS), the succinimide ester functionalized polyethylene glycol of formula VI is a four-arm polyethylene glycol succinimide ester (PEG) 4 -NHS), the succinimide ester functionalized polyethylene glycol of formula VII is a six-arm polyethylene glycol succinimide ester (PEG) 6 -NHS), the succinimide ester functionalized polyethylene glycol of formula VIII is an eight-arm polyethylene glycol succinimide ester (PEG) 8 -NHS)。
In one implementation of the application, the polyethylene glycol derivative is aldehyde modified polyethylene glycol.
In one implementation of the application, the structural formula of the aldehyde-modified polyethylene glycol is at least one of formula IX, formula X, formula XI and formula XII;
wherein z is an integer between 2 and 10000.
Preferably, the molecular weight of the aldehyde-modified polyethylene glycol is 2000-20000, preferably 2000-12000.
In the present application, the aldehyde-modified polyethylene glycol having the structural formula IX is a double-arm terminal aldehyde-modified polyethylene glycol (PEG) 2 -CHO), the aldehyde-modified polyethylene glycol of formula X being a four-armTerminal aldehyde modified polyethylene glycol (PEG 4 -CHO), the aldehyde-modified polyethylene glycol of formula XI is a six-arm terminal aldehyde-modified polyethylene glycol (PEG) 6 -CHO), the aldehyde-modified polyethylene glycol of formula XII is an eight-arm terminal aldehyde-modified polyethylene glycol (PEG) 8 -CHO)。
In one implementation of the application, the mass ratio of polyethylene glycol derivative to polylysine is 1 (0.1-500), preferably 1 (0.25-10).
In one implementation of the application, the medical gel dressing is an injectable gel or gel patch dressing.
The medical gel dressing of the present application may be an injectable gel or a gel patch dressing according to the need. In the case of injectable gels, the polyethylene glycol derivative and polylysine are placed separately and mixed and cured when needed to form the medical gel dressing of the present application. In the case of a gel patch dressing, the dressing may be a previously cured medical gel dressing.
In one implementation of the application, the medical gel dressing of the application is loaded with bioactive components and/or drugs.
The medical gel dressing of the present application may be loaded with bioactive components or deliver functional drugs according to the prior art, including but not limited to natural polyphenols, small molecule drugs, inorganic nanoparticles, growth factors, functional proteins, active polysaccharides, exosomes, liposomes, stem cells, probiotics, genes, RNAs, nucleic acids, active peptides, and modifications of these substances. Wherein the natural polyphenols include, but are not limited to, puerarin, curcumin, myricetin, procyanidins, catechin, quercetin, kaempferol, quercetin, caffeic acid, gallic acid, ellagic acid, and arbutin. The bioactive components loaded on the medical gel dressing of the present application include, but are not limited to, insulin-like growth factors, epidermal growth factors, platelet-derived proliferation factors, nerve growth factors, colony stimulating factors, transforming growth factor-alpha, bone morphogenic proteins, fibroblast growth factors, platelet-derived growth factors, erythropoietin, interleukin-like growth factors, and growth hormone release-inhibiting factors.
In another aspect, the application discloses the application of the medical gel dressing in preparing a tissue wound plugging and repairing material, a hemostatic agent, a medical adhesive, a tissue adhesion preventing material, a drug sustained-release material, a tissue regeneration bracket or a chronic wound dressing.
It can be understood that the medical gel dressing of the application has the advantages of high gelling speed, excellent mechanical property, strong tissue adhesiveness, good biocompatibility and biodegradability; therefore, the composite material can be used as a tissue wound blocking and repairing material, a hemostatic agent, a medical adhesive, a tissue adhesion preventing material, a drug slow release material, a tissue regeneration bracket or a chronic wound dressing.
In another aspect, the application discloses a method for preparing the medical gel dressing of the application, comprising the following steps:
(1) Preparing a polylysine solution, and marking the polylysine solution as a solution A;
(2) Preparing polyethylene glycol derivative solution, and marking as solution B;
(3) And mixing the solution A and the solution B, and curing the mixture at room temperature to form gel to obtain the medical gel dressing.
In the preparation method, the polyethylene glycol derivative and the polylysine can be rapidly solidified at room temperature to form the medical gel dressing, and the whole preparation method has the advantages of simple steps, easy operation, low cost of preparation raw materials and abundant sources, and is suitable for large-scale industrialized mass production.
In one embodiment of the application, the solution a and/or the solution B contains bioactive components and/or drugs.
When the medical gel dressing is loaded with the bioactive components and/or the medicines, the bioactive components and/or the medicines can be dissolved or dispersed in the solution A and/or the solution B, namely the bioactive components and/or the medicines can be independently dissolved in the solution A or the solution B, or the loading materials are partially dissolved in the solution A and partially dissolved in the solution B, and then the solution A and the solution B are mixed and cured at room temperature, so that the medical gel dressing loaded with the bioactive components and/or the medicines is obtained.
In one implementation of the application, the mass concentration of the solution A is 0.1% -50%, preferably 1% -10%.
In one implementation of the application, the mass concentration of the solution B is 1% -50%, preferably 5% -20%.
Due to the adoption of the technical scheme, the application has the beneficial effects that:
the medical gel dressing has the advantages of high gel forming speed, excellent mechanical property, strong tissue adhesiveness, good biocompatibility, biodegradability and the like, and can be effectively used for plugging wound bleeding. The medical gel dressing can be used as a tissue wound plugging and repairing material, a hemostatic agent, a medical adhesive, a tissue adhesion preventing material, a drug slow-release material, a tissue regeneration bracket or a chronic wound dressing, and has good clinical application value. In addition, the medical gel dressing has rich sources of raw materials and low cost.
Drawings
FIG. 1 is a graph showing statistics of gel forming time of a gel dressing for traditional Chinese medicine in accordance with an embodiment of the present application;
FIG. 2 is a graph showing the results of adhesive strength test of a gel dressing for medical use in the examples of the present application;
FIG. 3 is an observation result of the traditional Chinese medicine gel dressing according to the embodiment of the application after bending, twisting and extrusion at 0-90 degrees on pigskin;
FIG. 4 is a graph showing the results of compressive strength testing of a gel dressing for use in the present application;
FIG. 5 is an electron microscope image of a gel dressing for medical use in an embodiment of the application;
FIG. 6 is a swelling picture of a gel dressing for use in the present application;
FIG. 7 is a graph showing the results of an antibacterial property test of a gel dressing for medical use according to an embodiment of the present application;
FIG. 8 is a graph showing the results of a cell compatibility test of a gel dressing for medical use in accordance with an embodiment of the present application;
FIG. 9 is a graph showing liver hemostasis test results of a medical gel dressing in accordance with an embodiment of the present application;
FIG. 10 is a view showing the observation result of the healing effect of a traditional Chinese medical gel dressing according to the embodiment of the application;
fig. 11 is a view showing the observation result of the wound repair effect of the gel dressing for treating diabetic ulcers in the embodiment of the application.
Detailed Description
Polyethylene glycol (polyethylene glycol, PEG) is a class of synthetic polymers licensed for use in humans by the U.S. food and drug administration and has excellent biosafety. Another polymer material polylysine is a water-soluble polypeptide, contains rich amino groups, has the advantages of antibacterial activity, biodegradability and the like, and is regarded as a biological material with larger potential in the biomedical field. The medical gel dressing is obtained by creatively mixing and curing at least one polyethylene glycol in a formula V, a formula VI, a formula VII and a formula VIII, or at least one polyethylene glycol in a formula IX, a formula X, a formula XI and a formula XII with at least one polylysine in a formula I, a formula II, a formula III and a formula IV at room temperature.
Compared with the existing medical gel dressing, the medical gel dressing has the following advantages:
(1) The medical gel dressing has the advantages of simple preparation steps, easy operation, low cost of preparation raw materials and rich sources, and is suitable for large-scale industrialized mass production.
(2) The medical gel dressing can be formed in situ, can be prepared into any shape in different grinding tools, and can be applied to irregular wounds.
(3) The medical gel dressing has controllable gel forming speed and excellent mechanical property.
(4) The medical gel dressing can be covered on the wound of epidermis or viscera, can absorb tissue fluid, can be rapidly degraded in vivo and on the body surface after being used, is beneficial to dressing change of the wound and reduces the pain of wounded.
(5) The medical gel dressing has excellent hemostatic and visceral occlusion effects.
(6) The medical gel dressing has excellent anti-tissue adhesion effect.
(7) The medical gel dressing has good biocompatibility.
(8) The medical gel dressing can destroy cell membranes of bacteria and has a natural broad-spectrum antibacterial effect.
(9) The medical gel dressing has remarkable anti-inflammatory effect.
(10) The medical gel dressing has the effect of accelerating wound healing.
(11) The medical gel dressing can be used as a medical adhesive or a chronic wound healing dressing.
The application is described in further detail below with reference to specific examples and figures. The following examples are merely illustrative of the present application and should not be construed as limiting the application.
The terms used in the present application generally have meanings commonly understood by those of ordinary skill in the art unless otherwise indicated.
In the following examples, various processes and methods, which are not described in detail, are conventional methods well known in the art.
Example 1
The gel forming time of the medical gel dressing is tested in the embodiment, and the medical gel dressing formed by crosslinking succinimidyl ester functionalized or aldehyde modified polyethylene glycol with different arm numbers and polylysine with different structures through beta-carbonyl amide bonds or Schiff base bonds is prepared by the specific preparation method as follows:
(1) 5.0mg of linear polylysine was precisely weighed and dissolved in 1.0mL of PBS (pH 7.4) to obtain a mixture A. In this example, two 5.0mg portions of epsilon-polylysine (EPL) and two 5.0mg portions of poly-L-lysine (PLL) were weighed out to prepare solution A.
(2) 20.0mg of four-arm polyethylene glycol succinimidyl ester (PEG) was accurately weighed out respectively 4 -NHS), 20.0mg of four-arm terminal aldehyde modified polyethylene glycol (PEG) 4 -CHO), dissolved in 1.0mL PBS (pH 7.4), respectively, to give solution B.
(3) And respectively adding the solution A and the solution B into a double-tube syringe, extruding two liquids into a sample bottle at the same time, observing the flowing state of the liquids by inverting the sample bottle to judge the formation of gel, and recording the gel forming time.
EPL and PEG were specifically observed and recorded in this example 4 Gel time of NHS curing to form medical gel dressing, EPL and PEG 4 Gel time for CHO curing to form medical gel dressing, PLL and PEG 4 Gel time, PLL and PEG for curing NHS to form a medical gel dressing 4 Gel time for CHO curing to form a medical gel dressing, the results are shown in fig. 1.
The results in FIG. 1 show that EPL+PEG 4 -NHS、EPL+PEG 4 -CHO、PLL+PEG 4 -NHS、PLL+PEG 4 CHO forms hydrogels within 10 seconds. EPL+PEG 4 -NHS and PLL+PEG 4 Compared with EPL+PEG, the NHS hydrogel 4 -CHO and pll+peg 4 The gel formation time of CHO hydrogels is shorter.
Example two
The adhesive strength of the medical gel dressing is tested in this example, and the specific steps are as follows:
50. Mu.L of the solution A and the solution B of the first embodiment are respectively and uniformly coated on one end of a fresh back pigskin, the coating area is 1cm multiplied by 1cm, then the two ends of the pigskin are rapidly overlapped in opposite directions, the pigskin is fixed for 1min by a 100g weight at room temperature, and then the pigskin is stretched at a speed of 5mm/min until fracture occurs. The maximum shear adhesion strength of the medical gel dressing was recorded. Meanwhile, 100 mu L of hydrogel is coated on pigskin, and is bent, twisted and extruded at 0-90 degrees, so that the condition that the hydrogel adheres to the pigskin is observed. At the same time, the same test was performed using Fibrin glue (Fibrin glue) as a control. The results of the adhesion strength test are shown in FIG. 2, and the photographed results of the partial hydrogel adhered pigskin are shown in FIG. 3. In FIG. 3, (a) behavior EPL+PEG 4 Test pattern of NHS gel, (b) row and (c) row EPL+PEG 4 Test pattern of CHO gels, fig. 3 provides a graphic representation of only two gels, the remaining two gels also having similar effects.
The results in FIG. 2 show that EPL+PEG 4 -NHS and PLL+PEG 4 The adhesive strength of the formed NHS hydrogel is about 30kPa, EPL+PEG 4 -CHO and pll+peg 4 The adhesion strength of the CHO hydrogel is about 17kPa, which is far higher than that of commercial control fibrinAdhesive strength (4 kPa) of glue (Fibrin glue).
The observation result that the medical gel dressing is bent, twisted and extruded on the pigskin by 0-90 degrees shows that EPL+PEG 4 -NHS、EPL+PEG 4 -CHO、PLL+PEG 4 -NHS、PLL+PEG 4 All four gels-CHO-were able to adhere to pig skin as initially without falling off and had excellent adhesion properties, and the partial results are shown in FIG. 3.
Example III
The compressive strength of the medical gel dressing is tested in this example, and is specifically as follows:
the procedure for preparing the medical gel dressing of this example was the same as in example one, except that: the polylysine of solution A added was Hyperbranched Polylysine (HPL), i.e.the EPL of example one was replaced with an equal amount of HPL.
The solution A of this example was separately compared with the two solutions B of example one, PEG 4 -NHS and PEG 4 CHO, added separately to a double syringe, while extruding two liquids into a disc mold 15mm in diameter and 7.5mm in height, compression performance testing was performed using a dual column universal tester, compressing the hydrogel to 80% deformation or fracture at a compression rate of 1 mm/min.
The present example specifically tested HPL and PEG 4 Compressive Strength of NHS formed hydrogels, HPL and PEG 4 Compression strength of CHO formed hydrogels, test results are shown in fig. 4.
The results in FIG. 4 show that HPL+PEG 4 NHS to HPL+PEG 4 CHO hydrogels with higher compression modulus, hpl+peg 4 -NHS、HPL+PEG 4 The compression modulus of the CHO hydrogel compressed to 80% strain is 350.4 + -8.2 kPa and 327.5 + -4.4 kPa respectively, and the compression modulus of the medical gel dressing of this example is superior to that of physiological soft tissue, and has excellent mechanical properties.
Example IV
In this example, the medical gel dressing is observed by electron microscopy, and the specific steps are as follows:
the procedure for preparing the medical gel dressing of this example was the same as in example one, except that: the polylysine of solution A added was Dendritic Polylysine (DPL), i.e. the EPL of example one was replaced with an equal amount of DPL.
The solution A of this example was separately compared with the two solutions B of example one, PEG 4 -NHS and PEG 4 CHO, added separately to a double syringe, and simultaneously squeeze out both liquids into an orifice plate to obtain a hydrogel. Before the test, the hydrogel is subjected to freeze drying treatment, brittle fracture is carried out by liquid nitrogen, and the internal section is selected for observation by a scanning electron microscope. And (3) carrying out metal spraying treatment before testing, wherein the accelerating voltage is 5kV, and the amplification factor is 300 times and 500 times.
The present example is specific to DPL and PEG 4 Hydrogels formed by NHS, DPL and PEG 4 The hydrogel formed by CHO was subjected to electron microscopy and the results are shown in FIG. 5.
The results of FIG. 5 show that DPL+PEG at different magnification 4 -NHS and DPL+PEG 4 The CHO hydrogels all have three-dimensional porous network structure, which is favorable for permeation of water molecules and drug molecules, DPL+PEG 4 -NHS vs DPL+PEG 4 The pore structure of CHO hydrogels is denser.
Example five
The swelling test of the medical gel dressing is carried out in this example, and the specific steps are as follows:
the procedure for preparing the medical gel dressing of this example was the same as in example one, except that: the polyethylene glycol derivatives of the added solution B were respectively double arm polyethylene glycol succinimidyl esters (PEG 2 -NHS) and double arm terminal aldehyde modified polyethylene glycol (PEG 2 CHO), i.e. with equal amounts of PEG respectively 2 -NHS and PEG 2 CHO, PEG of alternative example one 4 -NHS and PEG 4 -CHO。
The EPL solution a of example one and the two solutions B of this example were added separately to a double syringe while two liquids were extruded and injected into a cylindrical glass mold. The weighed sample was put into 10mL of PBS, and the sample was taken out according to a set time, the surface water was sucked dry with filter paper, and the image was taken.
The present example separately observed EPL and PEG 2 Swelling of hydrogels formed by NHS, EPL and PEG 2 -CHO formationThe swelling of the hydrogels, and the results are shown in FIG. 6.
The results in FIG. 6 show that EPL+PEG 2 -NHS and EPL+PEG 2 CHO hydrogels achieve a swelling balance within 48h and the swelling volume is not very pronounced.
Example six
The antibacterial performance of the medical gel dressing is tested in the embodiment, and the specific steps are as follows:
the procedure for preparing the medical gel dressing of this example was the same as in example one, except that: the polyethylene glycol derivatives of the added solution B are respectively six-arm polyethylene glycol succinimidyl esters (PEG 6 -NHS) and six-arm terminal aldehyde modified polyethylene glycols (PEG 6 CHO), i.e. with equal amounts of PEG respectively 6 -NHS and PEG 6 CHO, PEG of alternative example one 4 -NHS and PEG 4 -CHO。
The EPL solution a of example one and the two solutions B of this example were separately added to a double syringe, and simultaneously two liquids were extruded and injected into an orifice plate to obtain a hydrogel. Respectively soaking 50mg of multifunctional hydrogel in 1mL of bacterial solution of Escherichia coli, staphylococcus aureus and Pseudomonas aeruginosa, wherein the concentration of bacterial solution is 1×10 7 CFU/mL, incubated with shaking at 37℃for 12h. By measuring OD 600 To determine the bacteriostatic action of the multifunctional hydrogel on bacteria.
The present example tested EPL and PEG, respectively 6 The antibacterial properties of the NHS-formed hydrogel against E.coli, staphylococcus aureus, pseudomonas aeruginosa were tested for EPL and PEG, respectively 6 The antibacterial properties of CHO-formed hydrogels against e.coli, staphylococcus aureus, pseudomonas aeruginosa are shown in fig. 7.
In FIG. 7, FIG. E.coil is EPL and PEG 6 NHS-formed hydrogels, EPL and PEG 6 Test results of antibacterial Properties of CHO-formed hydrogels against E.coli, FIG. P. Aeromonas EPL and PEG 6 NHS-formed hydrogels, EPL and PEG 6 Results of antibacterial property test of CHO-formed hydrogels against Pseudomonas aeruginosa, S.aureus is EPL and PEG 6 NHS-formed hydrogels, EPL and PEG 6 CHO-formed waterThe results of the antibacterial performance test of the gel against staphylococcus aureus are shown.
The results in FIG. 7 show EPL+PEG 6 -NHS and EPL+PEG 6 The antibacterial rate of the CHO hydrogel to the escherichia coli, staphylococcus aureus and pseudomonas aeruginosa is more than 95%, so that the multifunctional hydrogel can realize broad-spectrum antibacterial effect and has stronger antibacterial performance.
Example seven
The cell compatibility of the medical gel dressing is tested in this example, and the specific steps are as follows:
the procedure for preparing the medical gel dressing of this example was the same as in example one, except that: the polyethylene glycol derivatives of the added solution B are respectively eight-arm polyethylene glycol succinimidyl esters (PEG 8 -NHS) and octa-terminal aldehyde modified polyethylene glycol (PEG 8 CHO), i.e. with equal amounts of PEG respectively 8 -NHS and PEG 8 CHO, PEG of alternative example one 4 -NHS and PEG 4 -CHO。
The EPL solution a of example one and the two solutions B of this example were separately added to a double syringe, and simultaneously two liquids were extruded and injected into an orifice plate to obtain a hydrogel. Preparing a culture medium leaching solution of the aqueous gel according to the proportion of 10mg/mL, namely 10mg EPL+PEG 8 NHS hydrogel and 1mL of high sugar complete medium (brand Vison, cat No. C11995500BT, DMEM medium, 10% fetal bovine serum and 100IU/mL penicillin, streptomycin). Soaking for 24 hours at 37 ℃ in a cell culture box, then, discarding the common culture medium of the mouse fibroblast 3T3 inoculated on a tissue culture plate for 24 hours, replacing the common culture medium with a culture medium leaching solution containing aqueous gel, and culturing for 24 hours in the cell culture box at 37 ℃ and a carbon dioxide concentration of 5%, so as to obtain monolayer cells with good adhesion. Cell activity was measured using CCK-8 reagent, cell activity (%) = (OD) Hydrogel -OD Blank space )/(OD Culture plate -OD Blank space )。OD Hydrogel Refers to OD after 24h of culture in a medium containing hydrogel 600 A value; OD (optical density) Blank space Represents OD after 24h incubation with equal amounts of cell culture medium and CCK-8 solution without cells 600 A value; OD (optical density) Culture plate Representative of a non-aqueous gel extractOD after 24h culture in DMEM medium 600 Values.
EPL+PEG was tested separately in this example 8 -NHS and EPL+PEG 8 Cell compatibility of CHO two hydrogels, the results are shown in fig. 8. In FIG. 8, the Control group refers to the reference of the culture plate of the cells cultured in the normal DMEM medium without the hydrogel extract.
The results in FIG. 8 show that EPL+PEG 8 -NHS and EPL+PEG 8 The CHO hydrogel extract and the cells are incubated together for 24 hours, the cells treated by the hydrogel group show cell viability similar to that of the cells of the normal group, and the survival rate of each group is higher than 90 percent, so that the hydrogel has excellent cell compatibility.
Example eight
The liver hemostatic performance of the medical gel dressing is tested in this example, and the specific steps are as follows:
in this example, new Zealand white rabbits, males, 2-3kg were anesthetized with isoparaffin and tested. The rabbits were fixed on an operating table, the liver was exposed by carefully cutting the skin of the abdominal cavity, and a liver perforation bleeding model was produced on the liver of the rabbits using a 5mm punch. The solution A (EPL) of example one and the solution B (PEG) of example one were mixed 4 -NHS) and extruding two liquids simultaneously, 200. Mu.L (ES), EPL+PEG 4 NHS hydrogel is injected into the bleeding site, photographed and the hemostatic condition recorded. In addition, fibrin glue (Fibrin glue), a commercial product, was selected as a control group. The wound conditions were observed and photographed for 0min, 1s, 6s, and 5min after injection, respectively, and the results are shown in fig. 9. In fig. 9, the upper case is where ES is injected, and the lower case is where Fibrin glue is injected.
The results of fig. 9 show that in a rabbit liver perforation bleeding model, blood leakage occurs 5min after fibrin glue group hemostasis, and rapid blocking hemostasis is difficult; the ES hydrogel group of this example can complete hemostasis by only 6.+ -.1 s without any blood leakage, and can be used as a rapid hemostatic material.
Example nine
The scald wound healing effect of the medical gel dressing is tested by the embodiment, and the method is as follows:
the procedure for preparing the medical gel dressing of this example was the same as in example one, except that: the solution B contains puerarin with concentration of 0.1%.
20 SD rats, male, 250-300g, were selected, and after anesthesia with isoparaffin, deep II-degree scalding was performed on the backs of the rats with round metal copper blocks, further creating a round skin full-layer defect model with a diameter of 15 mm. Then the solution A (EPL) of example one and the solution B (PEG) of example one 4 -NHS), into double syringes, two liquids were simultaneously extruded, 200. Mu.L (ESM), EPL+PEG, was injected 4 The NHS+puerarin hydrogel dressing can rapidly cover and fill the wound, and the wound is photographed at 3, 7, 14, 21 and 28 days to observe the wound healing condition. Saline group (Control) and commercial product tergaderm TM The transparent dressing served as negative and positive control groups, respectively. The results are shown in FIG. 10. In FIG. 10, the top row is the photographed result of the Control of the normal saline group, and the middle row is the commercial product Tegaderm TM The bottom of the photographed results after the treatment is the photographed results after the hydrogel treatment in this example.
The results of fig. 10 show that the healing area of all groups of back wounds gradually decreased with increasing days, but ESM hydrogels were significantly more useful for treating scalded wounds than the saline group and the commercial control Tegaderm TM The healing area of the transparent dressing group is smaller, and almost no scar is left after healing, so that the medical gel dressing of the embodiment can obviously accelerate the repair of scalded wounds.
Examples ten
The repairing effect of the medical gel dressing on the diabetic ulcer wound surface is tested in the embodiment, and the repairing effect is specifically as follows:
the procedure for preparing the medical gel dressing of this example was the same as in example one, except that: the solution A contains insulin-like growth factor, and the solution B contains puerarin. Wherein the concentration of the insulin-like growth factor is 2.5%, and the concentration of puerarin is 0.1%.
40 SD rats, male, 250-300g, were selected, fasted and not water forbidden for 14h, weighed one by one, and were intraperitoneally injected with streptozotocin (60 mg/mL) to construct a model of type I diabetes rats. After the successful construction of the model by blood glucose determination, the model is determined to be sufficientThe sections create a circular model of a full-thickness defect of skin with a diameter of 5 mm. Then the solution A (EPL) of example one and the solution B (PEG) of example one 4 -CHO), separately added to a double syringe, simultaneously expressing two liquids, 200 μl (ESMP), i.e. epl+peg, is injected 4 The cho+puerarin+insulin-like growth factor hydrogel dressing rapidly covers and fills the wound, photographs the wound at regular intervals, measures the wound area with Image J software, and calculates the wound healing rate. Wound healing rate (%) = (S) 0 -S t )/S 0 ×100％，S 0 And S is t Represents the initial area of the wound and the area at time t, respectively, saline group (Control) and commercial Tegaderm TM The transparent dressing was used as negative and positive control groups, respectively, in this example, on days 7, 14 and 21, the tissue of the wound site was obtained and fixed in 4% paraformaldehyde solution, and after paraffin embedding, the sections were used and pathological analysis was performed on the sections. The wound healing rate statistics are shown in FIG. 11, and the Control group, commercial Tegaderm, is shown in the order from left to right in FIG. 11 on the abscissa TM Group and ESMP hydrogel group.
The results of FIG. 11 show that ESMP hydrogels when used to treat full-thickness defect wounds of foot ulcers and skin in diabetic rats, the 21-day wound healing rate reached 100%, had healed completely, whereas saline treated groups and commercial control Tegaderm TM The 21-day wound healing rates for the transparent dressing set were only 75% and 80%, respectively. The medical gel dressing of the example can obviously accelerate wound repair of diabetic foot ulcers.
The foregoing is a further detailed description of the application in connection with specific embodiments, and it is not intended that the application be limited to such description. It will be apparent to those skilled in the art that several simple deductions or substitutions can be made without departing from the spirit of the application.
Claims (10)
1. A medical gel dressing, characterized in that: mainly prepared by solidifying polyethylene glycol derivatives and polylysine.
2. The medical gel dressing of claim 1, wherein: in the curing process, the chemical bond formed by chemical reaction is a beta-carbonyl amide bond or a Schiff base bond;
preferably, the medical gel dressing has a three-dimensional gel skeleton structure.
3. The medical gel dressing of claim 1, wherein: the structural formula of the polylysine is at least one of a formula I, a formula II, a formula III and a formula IV;
wherein, m is an integer between 2 and 10000;
preferably, the molecular weight of the polylysine is 292-300000, preferably 3500-10000.
4. The medical gel dressing of claim 1, wherein: the polyethylene glycol derivative is succinimide ester functionalized polyethylene glycol;
preferably, the structural formula of the succinimide ester-functionalized polyethylene glycol is at least one of formula V, formula VI, formula VII and formula VIII;
wherein n is an integer between 2 and 10000;
preferably, the molecular weight of the succinimide ester-functionalized polyethylene glycol is 2000-20000, preferably 2000-10000.
5. The medical gel dressing of claim 1, wherein: the polyethylene glycol derivative is aldehyde modified polyethylene glycol;
preferably, the aldehyde group-modified polyethylene glycol has at least one of the structural formulas IX, X, XI and XII;
wherein z is an integer between 2 and 10000;
preferably, the molecular weight of the aldehyde-modified polyethylene glycol is 2000-20000, preferably 2000-12000.
6. The medical gel dressing according to any one of claims 1-5, wherein: the mass ratio of the polyethylene glycol derivative to the polylysine is 1 (0.1-500), preferably 1 (0.25-10);
preferably, the medical gel dressing is an injectable gel or gel patch type dressing.
7. The medical gel dressing according to any one of claims 1-5, wherein: the medical gel dressing is filled with bioactive components and/or medicines;
preferably, the bioactive component and/or drug comprises natural polyphenols, small molecule drugs, inorganic nanoparticles, growth factors, functional proteins, active polysaccharides, exosomes, liposomes, stem cells, probiotics, genes, RNAs, nucleic acids, active peptides, and modifications of at least one of these substances;
preferably, the natural polyphenol is at least one of puerarin, curcumin, myricetin, procyanidine, catechin, quercetin, kaempferol, quercetin, caffeic acid, gallic acid, ellagic acid and arbutin;
preferably, the bioactive component is at least one of insulin-like growth factor, epidermal growth factor, platelet-derived proliferation factor, nerve growth factor, colony stimulating factor, transforming growth factor-alpha, bone morphogenic protein, fibroblast growth factor, platelet-derived growth factor, erythropoietin, interleukin-like growth factor, and growth hormone release-inhibiting factor.
8. Use of a medical gel dressing according to any one of claims 1-7 for the preparation of a tissue wound plugging and repair material, a hemostatic agent, a medical adhesive, a tissue adhesion preventing material, a drug release material, a tissue regeneration scaffold or a chronic wound dressing.
9. A method of preparing a medical gel dressing according to any one of claims 1 to 7, characterized in that: comprises the steps of,
(1) Preparing a polylysine solution, and marking the polylysine solution as a solution A;
(2) Preparing polyethylene glycol derivative solution, and marking as solution B;
(3) And mixing the solution A and the solution B, and curing to form gel at room temperature to obtain the medical gel dressing.
10. The method of manufacturing according to claim 9, wherein: the solution A and/or the solution B contains bioactive components and/or medicines;
preferably, the mass concentration of the solution A is 0.1% -50%, preferably 1% -10%;
preferably, the mass concentration of the solution B is 1% -50%, preferably 5% -20%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311040584.0A CN116983466A (en) | 2023-08-16 | 2023-08-16 | Medical gel dressing and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311040584.0A CN116983466A (en) | 2023-08-16 | 2023-08-16 | Medical gel dressing and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116983466A true CN116983466A (en) | 2023-11-03 |
Family
ID=88523130
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311040584.0A Pending CN116983466A (en) | 2023-08-16 | 2023-08-16 | Medical gel dressing and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116983466A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104307052A (en) * | 2014-10-27 | 2015-01-28 | 北京爱美客生物科技有限公司 | Medicinal injectable anti-adhesive gel and preparation method thereof |
| CN105169469A (en) * | 2015-08-29 | 2015-12-23 | 北京诺康达医药科技有限公司 | Tissue sealant and preparation method and application thereof |
| CN105963792A (en) * | 2016-04-29 | 2016-09-28 | 深圳迈普再生医学科技有限公司 | Medical hydrogel composition, medical hydrogel as well as preparation method and application of medical hydrogel |
| CN107693838A (en) * | 2017-11-09 | 2018-02-16 | 杭州亚慧生物科技有限公司 | A kind of medical injectable gel and preparation method thereof |
| US20210162092A1 (en) * | 2018-08-10 | 2021-06-03 | Shanghai Ruining Biotechnology Co. Ltd | Medical hydrogel |
| CN114796609A (en) * | 2022-04-08 | 2022-07-29 | 上海瑞凝生物科技有限公司 | Application of polyethylene glycol hydrogel in preparation of self-adhesive biomedical material |
-
2023
- 2023-08-16 CN CN202311040584.0A patent/CN116983466A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104307052A (en) * | 2014-10-27 | 2015-01-28 | 北京爱美客生物科技有限公司 | Medicinal injectable anti-adhesive gel and preparation method thereof |
| CN105169469A (en) * | 2015-08-29 | 2015-12-23 | 北京诺康达医药科技有限公司 | Tissue sealant and preparation method and application thereof |
| CN105963792A (en) * | 2016-04-29 | 2016-09-28 | 深圳迈普再生医学科技有限公司 | Medical hydrogel composition, medical hydrogel as well as preparation method and application of medical hydrogel |
| CN107693838A (en) * | 2017-11-09 | 2018-02-16 | 杭州亚慧生物科技有限公司 | A kind of medical injectable gel and preparation method thereof |
| US20210162092A1 (en) * | 2018-08-10 | 2021-06-03 | Shanghai Ruining Biotechnology Co. Ltd | Medical hydrogel |
| CN114796609A (en) * | 2022-04-08 | 2022-07-29 | 上海瑞凝生物科技有限公司 | Application of polyethylene glycol hydrogel in preparation of self-adhesive biomedical material |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hao et al. | Carboxymethyl chitosan-based hydrogels containing fibroblast growth factors for triggering diabetic wound healing | |
| Yang et al. | Injectable adaptive self-healing hyaluronic acid/poly (γ-glutamic acid) hydrogel for cutaneous wound healing | |
| Chen et al. | Antibacterial adhesive self-healing hydrogels to promote diabetic wound healing | |
| Lu et al. | Mussel-inspired blue-light-activated cellulose-based adhesive hydrogel with fast gelation, rapid haemostasis and antibacterial property for wound healing | |
| JP7188779B2 (en) | Controllable self-annealing microgel particles for biomedical applications | |
| CN110128682B (en) | Sulfhydryl-aldehyde crosslinking hydrogel material and preparation method and application thereof | |
| Wang et al. | A double-crosslinked self-healing antibacterial hydrogel with enhanced mechanical performance for wound treatment | |
| JP6042815B2 (en) | Anti-adhesion barrier membranes using alginate and hyaluronic acid for biomedical applications | |
| US8163714B2 (en) | Injectable crosslinked and uncrosslinked alginates and the use thereof in medicine and in cosmetic surgery | |
| US6458386B1 (en) | Medicaments based on polymers composed of methacrylamide-modified gelatin | |
| Zhou et al. | Enzyme catalyzed hydrogel as versatile bioadhesive for tissue wound hemostasis, bonding, and continuous repair | |
| Wang et al. | Shape-recoverable hyaluronic acid–waterborne polyurethane hybrid cryogel accelerates hemostasis and wound healing | |
| US11191842B2 (en) | Injectable thermoresponsive polyelectrolytes | |
| RU2349347C2 (en) | Wound bandage including protein polymer and polyfunctional spacer | |
| US9636362B2 (en) | Pullulan regenerative matrix | |
| CN109568641B (en) | Medical sealing adhesive capable of promoting wound healing and preparation method thereof | |
| Guan et al. | Injectable gelatin/oxidized dextran hydrogel loaded with apocynin for skin tissue regeneration | |
| JP2011527913A (en) | Silica sol material comprising at least one therapeutically active ingredient for the production of biodegradable and / or absorbable silica gel materials for human medicine and / or medical technology | |
| KR102473363B1 (en) | Spray type hydrogel wound coating preparation method and Spray type hydrogel wound coating thereof | |
| Hou et al. | Development of a multifunctional injectable temperature-sensitive gelatin-based adhesive double-network hydrogel | |
| Zhao et al. | Biomimetic, highly elastic conductive and hemostatic gelatin/rGO-based nanocomposite cryogel to improve 3D myogenic differentiation and guide in vivo skeletal muscle regeneration | |
| Wang et al. | An antibacterial and antiadhesion in situ forming hydrogel with sol–spray system for noncompressible hemostasis | |
| Yang et al. | Injectable polylysine and dextran hydrogels with robust antibacterial and ROS-scavenging activity for wound healing | |
| Ding et al. | Photopolymerizable, immunomodulatory hydrogels of gelatin methacryloyl and carboxymethyl chitosan as all-in-one strategic dressing for wound healing | |
| CN114149598A (en) | Diabetes microenvironment responsive composite intelligent hydrogel and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |